Genflow Biosciences comes into focus as pet longevity demand grows

Genflow Biosciences Plc

Pet owners are spending more to keep animals healthier for longer. The shift now extends well beyond routine veterinary treatment, with growing interest in specialist diets, supplements, physiotherapy, mobility support and other products aimed at maintaining health and quality of life. Longevity is becoming easier for consumers to understand and more commercially visible.

The same ideas that have shaped human wellness are now being applied to pets. Owners are increasingly focused not only on treating illness, but also on preventing decline, supporting mobility and maintaining health as animals age. The emergence of terms such as “poochmaxxing” shows how far that mindset has moved into mainstream consumer culture.

The pet wellness market contains a wide range of products, and the scientific support behind them varies considerably. Some approaches have established veterinary backing, while others rely more heavily on marketing. As consumer interest grows, the difference between genuine science and loosely defined wellness claims is likely to become more important.

A market that increasingly questions whether longevity products actually work creates a clearer divide between science-led development and consumer wellness branding. Greater scrutiny can raise the commercial value of credible evidence while making it harder for poorly supported products to maintain their position.

Pet health is moving towards prevention. Owners are paying closer attention to weight, exercise, nutrition, mobility and age-related decline before serious health problems emerge. That creates a wider market around maintaining healthspan rather than simply responding to illness. For Genflow Biosciences, this puts longevity within a broader trend that is becoming increasingly visible to consumers and the animal health sector.

The pet wellness trend is moving from novelty towards a more established focus on healthy ageing. Consumers are already willing to spend, awareness of longevity is increasing and the demand for better evidence is becoming more pronounced. That combination creates a more favourable backdrop for science-led companies connected with ageing and longevity.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Pet food industry turns to healthy ageing as demand for longevity products grows

Growing interest in pet longevity is creating opportunities for specialised nutrition, supplements and veterinary treatments. Improved research into the needs of ageing cats and dogs could help manufacturers develop products with clearer evidence of their health benefits.

Genflow Biosciences CEO Dr Eric Leire discusses SIRT6 gene therapy results in aged dogs

Genflow Biosciences CEO Dr Eric Leire discusses interim SLAB-VET trial results, the potential of SIRT6 gene therapy in ageing dogs, plasmid DNA delivery, veterinary licensing opportunities and progress across the company's human gene therapy programmes.

Genflow reports biological age reductions in dog gene therapy study

Genflow Biosciences reports reductions in measured epigenetic age in dogs receiving SIRT6c gene therapy, selecting intravenous plasmid DNA as its lead veterinary delivery method while further follow-up continues.

Genflow Biosciences secures Japanese patent and expands animal health partnerships

Genflow Biosciences has secured Japanese patent allowance for its SIRT6 gene therapy, with all 16 claims approved, and signed additional confidentiality agreements with animal health companies. Its regional grant application is under review, with no impact on financial guidance expected.

Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus (video)

Genflow Biosciences’ latest SLAB-VET-001 results are sharpening the commercial case for its SIRT6c platform. CEO Dr Eric Leire discusses the signals seen in naturally aged dogs, why pDNA is leading the veterinary programme, growing interest from animal health companies and how progress could feed into Genflow’s human sarcopenia strategy.

Genflow Biosciences examines the role of genes in ageing

Genflow Biosciences is investigating a SIRT6 gene variant associated with longevity as part of its research into therapies targeting biological ageing.

Search